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Abstract 
Aims 
Modifications of antimicrobials’pharmacokinetic parameters have been reported in critically-ill 
patients, resulting in a risk of treatment failure. We characterizedamikacin pharmacokinetic 
variability in critically-ill patients with ventilator-associated pneumonia (VAP)and evaluated several 
dosing regimens. 
Methods 
We conducted a prospective multicenter study in critically-ill patients with presumptive diagnosis of 
Gram-negative bacilli (GNB) VAP. Patients empirically receivedimipenem and a single-dose 
ofamikacin,whichwas administered as a 30-minuteinfusion (20mg/kg). Concentrations were 
measured 0.5, 1, 8, 16 and 24 hours after beginning of infusion.Pharmacokinetic parameters were 
estimated using a population approach. Mainpharmacodynamic target was a ratio ≥10 between the 
concentration achieved 1 hour after beginning of infusion (C1h) and the minimal inhibitory 
concentration of the liable bacteria (MIC). We simulated individual C1h for severaldosing regimens by 
Monte Carlo method and computed C1h/MIC ratios for MICs from 0.5 to 64mg/L.  
Results 
Sixty patients (47 males), median (range) age and bodyweight: 61.5 years (28-84) and 78kg (45-126), 
respectively were included. Amikacin median C1hwas 45mg/L (22-87). Mean value (between-patients 
variability) for CL, V1, Q and V2 were 4.3L/h (31%), 15.9L (22%), 12.1L/h (27%) and 21.4L (47%), 
respectively. CL increased with CrCL (p<0.001) and V1 with body weight (p<0.001) and PaO2/FIO2 
ratio (p<0.001). With a 25mg/kg regimen, the pharmacodynamic targetwas achieved in20% and 96% 
for aMICs of 8 and 4mg/L, respectively. 
Conclusion 
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Amikacin clearance was decreased and its volume of distribution was increased as previously 
reported. A≥25 mg/kg single-dose is needed for empirical treatment of GNB-VAP. 
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Introduction 
Ventilator-associated pneumonia (VAP), defined as pneumonia occurring more than 48 h 
after the initiation of mechanical ventilation, is the most common hospital-acquired infection in the 
intensive care unit (ICU) [1]. Many previously published studies have shown that early and 
appropriate antibiotic therapy is associated with better outcome in critically-ill patients with severe 
infections[2].The latest guidelines of the American Thoracic Society and Infectious Diseases Society of 
America recommend that the empirical antibiotic therapy for late-onset pneumonia or in patients 
with risk factors for infection by multidrug-resistant pathogens should include a combination of an 
anti-pseudomonal-lactam and an anti-pseudomonalfluoroquinolone or an aminoglycoside such 
asamikacin[3].The superiority of once-daily dosing of aminoglycosides over multiple-daily dosing has 
been established[4]. However, no data supports a clinical benefit of a single-dose of aminoglycosides 
over multiple administrations. The rationale for an initial combination therapy is to broaden the 
antimicrobial spectrum of the empirical therapy; however some data suggest adverse effects linked 
to repeated administrations, such as adaptative resistance or nephrotoxicity. 
Amikacin, like other aminoglycosides, exhibits a concentration-dependent killing and 
producesa prolonged post-antibiotic effect. Previousclinical studies have shown that aratioof 10 or 
more between the concentration achieved 1 hour after the beginning of a 30-minute infusion (C1h ) 
and the minimal inhibitory concentration (MIC) of the bacteria responsible of the infection was 
predictiveof therapeutic success [5, 6]. Some authors recently suggested that a ratio between the 
area under the curve of concentration over time (AUC) and MIC (AUC/MIC) greater than 90 also has 
some predictive value for therapeutic success, with no difference in predictive capacities when 
compared to C1h / MIC ratio [7].Thosepharmacodynamic targets may be difficult to reach in critically-
ill patients for several reasons. First, large interindividual variations of amikacin pharmacokinetic 
parameters have been reported [8-10], with variations of C1hand AUC as a consequence. This 
variability is partially explained by total body weight and creatinine clearance, which are the most 
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frequently reported covariates of amikacin pharmacokinetic parameters[8-11]. Second, the current 
breakpoint of MICs defined by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) for Enterobacteriaceaespecies and Pseudomonas aeruginosa is 8 mg/L [12].  
Few authors investigated the amikacin dosage needed in a single infusion setting to achieve the 
defined pharmacodynamic target in a homogenous groupof patients hospitalised in ICU with 
suspected VAP. 
Using data from a prospective clinical trial, we aimed (i) to characterize amikacin 
pharmacokinetic parameters and their variability in ICU patients with suspected VAP, (ii) to study 
covariates of amikacin pharmacokinetic parameters, and (iii) toevaluate several amikacin dosing 
regimens using Monte Carlo simulations. 
Material and methods 
Patients and sampling 
This study is part of the IMPACTtrial, a prospective multicenterclinical trial conducted between 2009 
and 2011 inthreeICUs, at Bichat university hospital, Paris, France, and Victor Dupouy hospital, 
Argenteuil, France (ClinicalTrials #NCT00950222). 
Patients were included in the trial if they presented the following criteria: mechanical ventilation for 
more than 48 hours, a clinical suspicion of Gram-negative bacilli VAP, risk factors for multidrug 
resistant bacteria, and if a microbiologic sample was obtained before initiation of antimicrobial 
therapy using blinded protected telescoping catheteror bronchoalveolar lavage. Clinical suspicion of 
VAP was defined by the onset of new lung infiltrates on chest radiography, fever greater than 38.3°C, 
purulent tracheal aspirates or a leukocytosis> 10000/mL. Risk factors for multidrug-resistant bacteria 
were antimicrobial therapy in the preceding 15 days or late-oŶset VAP ;≥6 daysͿ[3]. Patients were 
not eligible if they were younger than 18-year-old, if they had renal failure requiring renal 
replacement therapy or received a treatment by imipenem or amikacin at the time of inclusion. 
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Written consent was obtained from patients or their legal representative. The study was approved by 
the Ethics Committee of the Hôtel-Dieu university hospital (APHP, Paris). 
All patients were treated with a combination of imipenem and amikacin.Imipenem was administered 
every 8 hours over a 30-minute infusion and should not be changed for the first 48 hours. Doses 
ranged from 500 mg to 1000 mg, according to creatinine clearance (CrCL).Amikacintreatment 
consisted in onesingle 30-minute infusion of a suggested dose of 20 mg/kg administered the first day 
of antimicrobial therapy. This dose was recommended by guidelines at the time of this study was 
designed [3]. 
De-escalation therapy was encouraged after isolation of the Gram-negative pathogen and obtaining 
the results of susceptibility tests. 
Usual clinical and demographic characteristics were recorded at ICU admission, as well as ventilator 
parameters, two scores for assessment of severity (SOFA [13]and SAPS-II [14])and routine biologic 
markers. 
Blood samples were collected 0.5, 1, 8, 16 and 24 hours after the onsetof infusion. Exact times of 
beginning and end of infusion were recorded, as well as exact sampling times. Amikacin 
concentrations were determined by fluorescence polarization immunoassay using the 
amikacinInnofluor® kit[15]. The limit of quantification of the technique is 0.5 mg/L, and coefficients 
of variation for intra- and inter-assay were4.1% and 5.8%, respectively. 
Population pharmacokinetic analysis 
Basic model 
Population pharmacokinetic analysis was performed using the Stochastic Approximation Expectation 
Minimization (SAEM) algorithm in Monolix v4.2 (Lixoft, Orsay, France, available at 
http://www.lixoft.com). This algorithm handles concentrations below the limit of quantification to 
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improve parameters estimation [16]. We used the total dose administered to each patient for model 
building. 
Both one- and two-compartment(s) models with first order elimination were tested[8, 10, 11, 17].  
We used an exponential random effects model for each pharmacokinetic parameter. We assumed 
the random effects to have a normal distƌiďutioŶ ǁith a ŵeaŶ of Ϭ aŶd a ǀaƌiaŶĐe of ω2. Correlation 
() between individual random effects was kept in the model if the estimated correlation coefficient 
ǁas ≥ Ϭ.Ϯ. The residual error model was supposed to be additive, proportional or combined, with a 
being the standard deviation of the additive component and b the standard deviation of the 
proportional component. 
The best model was chosen using the Bayesian information criteria (BIC), derived for each model 
from the computation of likelihood by importance sampling[18]. 
Covariate model building 
The influence of the following covariates at initiation of treatment on amikacin pharmacokinetic 
parameters was tested: 3 demographic variables (age, gender and total body weight), 2 clinical 
variables (shock and edema score[19]), 2 severity scores (SOFA[13] andSAPS-II[14]), 2 ventilator-
related parameters (PEEP and PaO2/FIO2 ratio) and 3 biochemical markers (serum albumin, total 
bilirubin and 4-hour creatinine clearance). Four-hour creatinine clearance was calculated using serum 
creatinine level and a 4-hour urine collection at the day of inclusion. This approach has been 
validated for monitoring renal function in critically-ill patients[20]. Missing values for tested 
covariates were imputedto the median value observed in the analysis population.Steps for selection 
of covariate model are described in Online Resource 1. 
Final model determination 
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We graphically studied the influence of covariates on their related pharmacokinetic parameters. 
Outliers were studied and excluded from analysis when there was a suspicion of incomplete data 
collection, in particular for creatinine clearance which was estimated using a 4-hour urine collection.  
Patients for whom covariates had been imputed were also excluded. The covariate model was 
adjusted to the reduced population obtained after exclusion of these patients, and a backward 
selection method was used in order to obtain a final model in which all covariates had a p-value < 
0.05 using the likelihood-ratio test. 
The coefficient estimated for creatinine clearance was compared to 1 using the likelihood ratio test. 
Model evaluation 
Evaluation of the final model was conducted using graphical methods. Basic goodness-of-fit plots 
were used, as well as the individual weighted residuals (IWRES) and the normalized prediction 
distribution errors (NPDE) over time and the visual predictive check (VPC).NPDE and VPC were 
generated using 500 Monte Carlo simulations.  
Evaluation of doses by simulation 
Using the estimated distribution of amikacin pharmacokinetic parameters in the final model with 
covariates, we simulated amikacin concentration obtained 1 hour after the start of a 30-minute 
infusion and AUC for 1000 patients by Monte Carlo simulation for several dosing regimen. This timing 
for amikacin sampling is commonly used for studying amikacin efficacy[17].For pharmacokinetic 
simulations, we randomly re-sampled 1000 vectors of covariatesamong those observed in the 
patients included in the analysis and simulated individual pharmacokinetic parameters from their 
estimated distribution in the final model with covariates. Simulated doseregimens were the 
following: 20, 25, 30, 35 and 40 mg/kg. We computed the probability to achieve a C1h/MIC ratio ≥ ϭϬ 
aŶd aŶ AUC/MIC ƌatio ≥ 9Ϭ for MICs ranging from 0.25mg/L to 64mg/L for each or these dosing 
regimens. These values are usually observed in clinical practice 
Page 9 
 
(http://www.eucast.org/mic_distributions/), with an 8 mg/l susceptibility breakpoint for 
Enterobacteriaceaespecies and Pseudomonas aeruginosa. 
Results 
Patients’ characteristics 
Of the 61 patients included in the IMPACTtrial, one had a kinetic profile which was not compatible 
with a unique injection and was withdrawn from analysis. Thus, data from 60 patients were available 
for modelling. PatieŶts’ characteristics are presented in Table 1. Median (min – max) age and total 
body weight were respectively 61.5 years (28 – 84) and 78 kg (45 – 126), andmost patients were 
males (n=47, 78%). At inclusion, 26 patients hadseptic shock (43%). Median SAPS-II and SOFA scores 
were 42 (19 – 90) and 7 (2 – 17), respectively,andmedian 4-hour creatinine clearance was 82 mL/min 
(4 – 412). 
Pharmacokinetic data and modelling 
A total of 291 values of amikacin concentrations were available, with a median of 5 per patient (3 – 
5). Median amikacin dose administered was 20 mg/kg (11 – 28). Median serum concentration 
observed 1 hour after the beginning of infusion was 45 mg/L (22 – 87). Individual observed 
concentrations are presented in Figure 1. Fourteen values (4.8%) of amikacin concentration were 
below the limit of quantification. 
Serum concentrations were best described by a 2-compartment model with a combined residual 
error model (Online Resource 2). Correlations between estimates in the basic model were ≥ 0.2 
between all individual random effects, and thus kept in the analysis. In this model, amikacin 
clearance (CL) was estimated to 4.0L/h, central volume of distribution (V1) to 15.3L, peripheral 
volume of distribution (V2) to 22.1L and inter-compartmental clearance (Q) to 12.2 L/h (Table 2). 
Their relative standard errors were satisfactory, all being <10%. The inter-individual variability of 
pharmacokinetic parameters ranged from 30% for Q, to 60% for CL. Estimates of inter-individual 
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variability of pharmacokinetic parameters were also satisfactory (Table 2). The goodness of fit plots 
of this model without covariate did not show any model deficiency (data not shown). 
Among the 12studiedcovariates, 8 were significantly associated with the individual Bayes estimates 
of pharmacokinetic parameters (Online Resource 1).The best model included 4 covariates (Online 
resource 1): creatinine clearance for CL, total body weight and PaO2/FIO2 ratio for V1, and creatinine 
clearance for V2. Two patients presented a low creatinine clearance but a high amikacin clearance. 
Their individual fits were satisfactory, and we hypothesised that their urine collection was 
incomplete. They were excluded from the analysis. In another patient, amikacin clearance was 
estimated to 11 mL/min, but creatinine clearance was missing and had been imputed to the median 
value. The 5 patients in whom creatinine clearance was not available were excluded. The 4-covariate 
model was adjusted to the 53 remaining patients. 
Creatinine clearance was no longer a significant covariate for V2 (p=0.4), and the final model 
included 3 covariates: creatinine clearance (p<0.001)for CL, total body weight(p<0.001) and 
PaO2/FIO2 ratio (p<0.001) for V1 (Table 2).The coefficient for creatinine clearance on CL was 
significantly different from 1 (p<0.001).The variations of pharmacokinetic parameters according to 
covariates are presented in Figure 2. All three of them were positively correlated with the 
pharmacokinetic parameters. Amikacin clearance was estimated in the final model at4.3 L/h (72 
mL/min), V1 at 15.9L and V2 at 21.4 L (Table 2).Variance – covariance matrix between the individual 
random effects is presented in Online Resource 3. 
Goodness-of-fit plots did not show any model misspecification. The IWRES and NPDE were centered 
to zero and did not show any trend over time (Online Resource 4). The VPC did not show any model 
deficiency (Figure 3). 
Pharmacokinetic simulations 
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Probabilities to achieve a C1h/MIC ƌatio ≥ ϭϬ aĐĐoƌdiŶg to the single-dose of amikacinsimulated and 
MICs are presented in Figure 4. A20 mg/kg dosewas sufficient to achieve the pharmacokinetic target 
in 100%of patients for a MIC of 2 mg/L or less. With this dose only 80% and 4% of patients achieved 
the target for a MIC of 4 and 8 mg/L, respectively. With a25mg/kg simulated infusion, the probability 
to reach the target was 96% for a MIC of 4 mg/L and 20% for a MIC of 8 mg/L. With the 40 mg/kg 
regimen, the probability to achieve a C1h/MIC ƌatio ≥ ϭϬ was 80% for a MIC of 8 mg/L (Figure 
5).Online Resource 5 presents the boxplots of the 1000 simulated C1h/MIC ratio for a MIC of 8 mg/L, 
for doses from 20 to 40 mg/kg. 
Results were similar when considering the target of AUC/MIC ≥ 90 (Online Resource 6). With a dose 
of 20 mg/kg, 90% of patients achieved the target for a MIC of 2 mg/L or less, but this proportion was 
below 20%for a MIC value of 8 mg/L. Simulations for a dose of 25 mg/kg showed that 69% of patients 
achieved the pharmacodynamic target for a MIC of 4 mg/L, but only 22% did for a MIC of 8 mg/L. An 
increase to 40 mg/kg led to an increase of the probability to reach the pharmacodynamic target to 
90% and 52% for a MIC of 4 mg/L or 8 mg/L, respectively. 
Discussion 
 The present study confirms that the 20 mg/kg single-dose regimen traditionally used is not 
adequatebased on the analysed pharmacokinetic and pharmacodynamic indices and thatamikacin 
dosing regimen should be increased to at least 25 mg/kg for critically-ill patients when initiating 
empirical amikacin therapy for VAP caused by a Gram-negative rod. This increase has been recently 
suggested by Taccone et al [17]. To our knowledge, few data supported this recommendation[21, 
22]. Those studies did not use a population approach and were performed in patients with severe 
sepsis or septic shock, thereby gathering patients with different varieties of infection. Although the 
influence of the nature of infection has not been thoroughly examined, some authors suggested that 
the clinical diagnosis might influence the pharmacokinetic parameters of aminoglycosides [10]. We 
focused our analysis on an homogenous group of patients. Our simulation-based analysis, using data 
Page 12 
 
from a prospective multicenter trial and a solid methodology, confirms theresults of Tacconeet al 
[17], and suggest that a higher initial dose is necessary, at least in patients requiring mechanical 
ventilation. 
A comparative study of different initial amikacin dosing regimen would confirm our conclusions. It 
would also allow to study the impact of higher doses on renal function. Nephrotoxicity is a well-
known adverse effect of aminoglycoside therapy. However, this effect has beenassociated with 
duration of therapy[23].Available studies suggest that short-course treatments would allow to 
minimize toxicity while keeping maximal efficacy [24]. In the majority of severe infections, 
aminoglycosides are administered as a single infusion in combined antimicrobial therapy. Higher 
single doses would therefore have potentially limited or no effect on renal function, as suggested by 
recent studies [21, 22]. It should also be noticed that neuromuscular blockade might have an 
increased frequency when using higher doses of aminoglycosides [25]. Its main manifestation is 
respiratory weakness, and this side effect is reversible. It would have a limited impact on patients 
with mechanical ventilation. 
Another result is thatamikacin clearance and volume of distribution were estimated to 
approximately 70 mL/min and 37 L, respectively. These values were in accordance with published 
data on ICU patients. This confirms the issues observed in antimicrobial pharmacokinetic parameters 
in critically-ill patients [26, 27], i.e.adecreaseof drug clearance and an increaseof volume of 
distribution [28-32]. Significant covariates were 4-hour creatinine clearance for amikacin clearance, 
and total body weight and PaO2/FIO2 ratio for central volume.  
The association between total body weight and volume of distribution has already been reported [9, 
10, 33], and administered amikacin doses are commonly adjusted to total body weight. It is still not 
clear which measure of body size best describes pharmacokinetic parameters.A recent meta-analysis  
explored the relationship between drug clearance and body size metrics [34]. The authors found that 
lean body weight to the exponent 2/3 was more suitable for describing the relationship between 
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drug clearance and body size. However, they did not question the link between the volume of 
distribution and body size, and this conclusion may not apply for all pharmacokinetic parameters. As 
body size was not collected in the IMPACT trial, we could not investigate the effect of this weight 
metrics or of body mass index on amikacin pharmacokinetic parameters. For hydrophilic drugs such 
as aminoglycosides, data on the influence of lean body weight and drugs volume of distribution are 
lacking and would be of interest. 
The BIC was not improved by adding total body weight as a covariate for V2. This is quite 
unexpected, and V2 might represent a weight-independent compartment in which amikacin 
accumulates. It has previously been shown that total urine recovery of amikacin isnot complete 24 
hours after its administration, and that aminoglycosides including amikacin accumulates in the 
kidney[35, 36]. 
 We found a high interindividual variability in amikacin pharmacokinetic parameters as 
previously reported in studies performed among critically-ill patients [8, 37]. Significant covariates 
reducedthis variability, with a 50% maximal decrease for amikacinCL in our study. To our knowledge, 
no published covariate model could fully explain the observed interindividual variability. It is 
therefore highly probable that inside diagnosis-homogenous groups of patients, subpopulations exist 
that are not individualized by usual covariates. Such variability makes the choice of the optimal 
dosing strategy extremely challenging from an individual perspective. Considering the absence of 
severe adverse effect expected in a single-dose setting,mechanically-ventilated patients in intensive 
care units should receive a high amikacine dose in order to maximize the probability of 
pharmacodynamic target attainment. Further studies should furthermore focus on identification of 
covariates allowing for reducing the high unexplained interindividual variability. 
 The main limitation of this study is that it was restricted to a limited number of patientswho 
had a suspicion on VAP. Therefore the results may not apply to patients who do not require 
mechanical ventilation. Nevertheless, the French surveillance network of nosocomial infections 
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recently reported that about 60% of patients hospitalized in ICU would require mechanical 
ventilation during their stay[38]. Another limitation is the use of the MIC breakpoint for Monte Carlo 
simulations. To our knowledge, no published data report the distribution of MICs for Gram-negative 
bacilli responsible for infection in intensive care units. As bacteria involved in infection of critically-ill 
patients frequently have higher MICs than those isolated from patients hospitalised in other wards, 
we did not use published MICs distributions that gather strains obtained from all wards. A recent 
study of MIC breakpoints based on simulations suggested that pharmacokinetic – pharmacodynamic 
breakpoints are similar to those defined by the EUCAST or the CLSI [39]. In the empirical setting, the 
worst-case assumption should be preferred when initiating an antimicrobial therapy.This approach is 
currently used for pharmacokinetic-pharmacodynamic simulations [17, 40, 41]. However, it is likely 
that the majority of Gram-negative rods involved in critical infections have a MIC below 8 mg/L.For a 
MIC of 4 mg/L, 96% of patients achieved a C1h/MIC ratio ≥ 10 after a dose of 25 mg/kg in our 
simulations. 
 In conclusion, amikacin pharmacokinetic parameters values were similar to those previously 
reported. This study confirms recent results for the determination of the initial amikacin dose 
required in critically-ill patients. An empirical dose of 25mg/kg or more is needed to achieve the 
amikacinpharmacodynamic predictors of clinical efficacyin Gram-negative bacilli infections. Other 
studies are needed to prospectively evaluate these conclusions in order to improve the management 
of patients with severe infections. 
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